Member Info for HotblackDesiato

Hi Laz - I guess a lot hinges on getting a deal for 1801. It could be a partner will pay for all future development but want 50% ownership of 1801. No dilution but no increase in the SAR coffers either. On the other hand, if we were to get £X million for a share of 1801, depending on the size of the deal we may be able to accelerate 1802 through manufacturing and into the clinic.

Now if someone wants 1801 AND 1802, well, who knows where that might lead...

Perhaps the translational studies are coming to an end and they now know which direction(s) to take 1802.

If we were to get a sizeable upfront partnership or license fee for 1801 it would probably be used primarily to advance 1801/2 (depending on what the other party can bring to the table). Assuming we'd have a healthy bank balance, I wonder if the BoD would consider taking another crack at the FLT3+Aurora solubility issue. AI and machine learning has advanced since they last looked at the compound so it may be worth another look.

An interesting read - https://www.patheon.com/us/en/insights-resources/blog/predictive-modeling-for-solubility-and-bioavailability-enhancement.html

Regards.

Hi All, even if 1801 results don't appear this week I can't see the sp falling from its current level as anticipation grows.

I presume the evidence from the covid research will have added significantly to the safety profile, allowing us to skip the P1b stage of the Oz trials. Looks like 1801 might be something quite special.

Must remember to set the alarm clock for 7am tomorrow just in case there's something to report.

Hi Silver - the sp is still licking its wounds from the RF fiasco. Solid news from Oz and a reminder to the market of the current revenue from global psoriasis treatments should put things back on track. The biomarkers should also point to what other conditions 1801 may be able to treat. Add in these potential other revenue streams and who wouldn't want a slice of that pie?

Getting 1801 to market is still years away even if it proves to be highly effective but we should reap the reward sooner than that.

The BoD should know by now if they're on target to announce 1801 trial results before the end of the month. If they aren't confident of meeting that self-imposed timeline then they should maybe at least issue an RNS (this week?) to say something along the lines of, 'whilst patient participation in the P1a trial is now complete, we await the final data sign-off from the authorities in Oz and look forward to sharing it with the market in the coming weeks.'

This would at least let us know they aren't the cause of any holdup and it might steady any investor jitters. The BoD are often reminded that their self-imposed deadlines are regularly missed so if they can avoid further grief at the next meeting then it might be worth a small update if they know the data won't be ready in time.

The market is a fickle beast and it never misses an opportunity to overdo any drop. Whilst awaiting the data, I just hope the BoD have been brushing up on their business acumen.

Regards.

It certainly looks like someone intentionally applied the brakes to 737 development, SOG. Although we'll never know the absolute truth of the matter, you'd hope when negotiating the latest deal that the CPF would try to ensure some level of urgency in moving 737 to the next stage. Perhaps that's just an idealist's point of view though.

On the brighter side, 1801 news must be just about peeking over the horizon - set your sp compass to head north from here!

Hi SOG - no matter how frustrated we punters are with the glacial progress of 737, imagine how Tim & John feel. They must be tearing their hair out.

For any new investor here wondering why we keep banging on about SRA737, what sets it apart from other CHK1 inhibitors in its class is -

Potency and Selectivity: SRA737 has shown significant potency in preclinical studies, demonstrating its ability to inhibit CHK1 effectively at lower concentrations compared to other inhibitors. Its selectivity for CHK1 also minimizes off-target effects, reducing the risk of side effects associated with broader cellular targets.

Pharmacokinetic Properties: SRA737 has a favorable pharmacokinetic profile, with a half-life of 8.6–13.8 hours, which allows for once-a-day dosing. This is advantageous for patient compliance and convenience, potentially improving the overall effectiveness of the treatment regimen.

Clinical Development: SRA737 has progressed through early clinical trials, including a phase I trial evaluating its safety and efficacy both as a monotherapy and in combination with gemcitabine. These trials have laid the groundwork for understanding its therapeutic potential across various cancer types.

Combination Therapies: The exploration of SRA737 in combination therapies, such as with low-dose gemcitabine, highlights its potential for enhancing the anticancer effects of existing treatments. This approach could lead to improved outcomes for patients with advanced cancers.

Despite its current whereabouts being shrouded in mystery, there is clear clinical evidence that it could prove to be a gamechanger if it gets the development it deserves.

I feel the BoD need to provide some sort of update even if they still can't disclose who has licensed it. At least if we know it's got someone's full attention then that may nudge the sp a little.

Nicely - only in your household.

Laz - can't even find mention of solicitors in the various annual reports etc. that I've just trawled through.

Whichever way you slice it, we're a day closer to news on 737, 1801 & perhaps even the end of the translational studies for 1802.

Sorry, no idea, Laz. I've just looked at the Wayback Machine at https://web.archive.org/ to see if I could compare things but the advisors page isn't available.

Whilst we await progress, we might as well start rumours that we have new solicitors to help with license agreement contracts!

Aha, page now updated - https://sareum.com/sareum-advisors/

Hi Aber - your suggestion is plausible since the BoD didn't give any reason for their removal as broker. So the next question would be, did PH themselves ask to be removed as broker to distance themselves from any conflict of interest?

It's all getting quite exciting.

Morning All - oddly the SAR website has been updated to remove mention of the recent BIO convention but PH are still noted as a co-broker. A strange oversight. Perhaps the BoD have commissioned a new-look website that will go live when 1801 results are announced so there is minimal site maintenance for the current one.

I've previously contacted the web company when I've spotted errors and they are corrected the next day. Not this time, which makes me think a new website is in the offing.

Morning Ben, I'm not sure about peer review as such since all the preclinical work will be reviewed by whichever national body (MHRA!) gives approval for an in-human drug trial to take place.

A number of us here have posted various preclinical studies relating to 737 and they each show it appears to work. I haven't found anything on other research groups using 1801 yet but I think those will come in time once our own results are announced. An outside research group would probably want to wait until the drug originator has at least completed P1a to know if it's worth persuing for their own objectives.

Not so long ago Scotland had more pandas than Tory MPs. Soon the whole of the UK will have more Minotaurs than Tory MPs.

(For balance, other useless political parties are available. Always read the label. Keep away from children.)

Hi Megs - no worries, I thought you might have found something on 737 or that TM had signed a deal whilst in the US.

Don't let the buggers grind you down.

Regards.

Hi Meg - is there something you're not telling us?

I hope you're not just teasing. It's a bit like that old gag, how do you keep an idiot in suspense? I'll tell you tomorrow.

And while I'm here, what's the difference between pink and purple? Your grip.

Hi Celtic - the autoimmune pipeline entry (link below) implies 1801 could be a strong contender in that area. I'm only guessing but the bloodwork results from Oz should at least indicate what disease markers are being triggered (if that's the right terminology!)

https://sareum.com/research-development/

These discoveries will make the Oz trial results all the more exciting when they're finally announced. Fingers-crossed, anyway!